Ver­tex says an­oth­er type 1 di­a­betes pa­tient is in­sulin-free in up­dat­ed da­ta out of EASD

Ver­tex Phar­ma­ceu­ti­cals’ islet cell ther­a­py has pro­duced more promis­ing ear­ly da­ta in type 1 di­a­betes pa­tients, with a third reach­ing in­de­pen­dence from in­sulin and all six re­port­ing im­prove­ments in HbA1c.

Back in June, the com­pa­ny had an­nounced that two pa­tients in the Phase I/II tri­al eval­u­at­ing VX-880 were in­sulin-free af­ter un­der­go­ing treat­ment. Now, in da­ta pre­sent­ed Tues­day at the Eu­ro­pean As­so­ci­a­tion for the Study of Di­a­betes an­nu­al meet­ing, Ver­tex shared ad­di­tion­al de­tails about those pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER